摘要
目的分析肾性贫血治疗中罗沙司他联合生血宝合剂的应用价值,以期进一步提升疾病治疗有效率。方法选取2020年2月—2022年7月于蚌埠市第三人民医院进行治疗的92例肾性贫血患者,通过数字随机法将患者分为两组,每组46例,对照组患者实施罗沙司他治疗,研究组患者实施罗沙司他联合生血宝合剂治疗,对比两组治疗前后炎性因子指标、贫血指标以及不良反应发生率。结果治疗后研究组IL-6、IL-8水平均低于对照组,差异有统计学意义(P<0.05),且研究组CRP水平为(6.32±2.09)mg/L,低于对照组(8.67±2.49)mg/L,差异有统计学意义(t=4.903,P<0.05);治疗后,研究组Hb、RBC、Hct指标高于对照组,差异有统计学意义(P<0.05);研究组患者治疗期间不良反应发生率为8.70%,与对照组相比,差异无统计学意义(χ^(2)=0.449,P=0.503)。结论对肾性贫血患者实施罗沙司他联合生血宝合剂治疗能够有效改善患者贫血指标,抑制患者炎性反应,应用效果理想。
Objective To analyze the application value of Roxadustat combined with Shengxuebao mixture in the treatment of renal anemia,in order to further improve the treatment efficiency.Methods The ninety-two patients with renal anemia who received treatment in Bengbu Third People's Hospital from February 2020 to July 2022 were selected.The patients were divided into two groups by digital random method,with forty-six cases in each group.Control group was treated with Roxadustat,and study group was treated with Roxadustat combined with Shengxuebao mixture.The inflammatory factor index,anemia index and the incidence of adverse reactions were compared between the two groups before and after treatment.Results After treatment,the levels of IL-6 and IL-8 in the study group were lower than those in the control group,the difference was statistically significant(P<0.05).The CRP level was(6.32±2.09)mg/L in the study group,lower than(8.67±2.49)mg/L in the control group,and the difference was statistically significant(t=4.903,P<0.001).After treatment,Hb,RBC and Hct indexes in the study group were higher than those in the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 8.70%,and there was no statistically significant difference compared with and the control group(χ^(2)=0.449,P=0.503).Conclusion Roxadustat combined with Shengxuebao mixture can effectively improve the anemia indexes and inhibit the inflammatory response of patients with renal anemia,and the application effect is ideal.
作者
张银霞
曹磊
ZHANG Yinxia;CAO Lei(Department of Nephrology,Bengbu Third People's Hospital,Bengbu,Anhui Province,233000 China)
出处
《世界复合医学》
2023年第4期141-144,共4页
World Journal of Complex Medicine
基金
蚌埠医学院自然科学重点项目(BYKY2019269ZD)。
关键词
罗沙司他
生血宝合剂
肾性贫血
贫血指标
炎性因子
Roxadustat
Shengxuebao mixture
Renal anemia
Anemia index
Inflammatory factor